12:00 AM
Nov 08, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Synagis palivizumab: Marketed

MEDI reported data from 2 surveys evaluating Synagis' efficacy during the 1998/1999 RSV season. A survey of 1,839 patients showed a 2.3 percent RSV hospitalization rate for Synagis-treated patients compared to...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >